Biotech Values

[mcbio]

ENTA -

The study also included those who were not cured with previous treatment with sofosbuvir (SOF) plus ribavirin (RBV) or with interferon (IFN) plus RBV, with or without SOF (44 patients, 42 percent).

What percentage of this 42% was specifically SOF+RBV or IFN+RBV+SOF? Just trying to get a sense of what percentage SOF does not generally work on in this specific population. And is there some specific reason as to why ENTA-based regimen works in this specific population where SOF does not?